GYN Flashcards
Minimum evaluation of complaint of urinary incontinence
History: leak as social problem; severity and goals; frequency (8x/day nml), nocturia (1x/night nml), dysuria, urgency; aggravating factors; timing of leakage; PMH–DM, MS spinal cord trauma/injury; PSH–spine, radiation, bladder surgery; meds–diuretics, EtOH, narcotics, antihistamines, caffeine, alpha agonists/blockers, CCB
UA and cx
Exam: obesity, prolapse–assess all support, degree of estrogenization, neuro-exam; demonstration of SUI, measurement of urethral mobility, PVR (abnml >150)
UUI tx
anti-muscarinic meds: oxybutynin/tolterodine/solifenacin
block parasympathetic M2/m3 receptors to inhibit involuntary detrusor contraction
SE: dry mouth, eyes and constipation
Contra-indications: narrow angle glaucoma, urinary retention gastric retention/obstruction
Beta 3 adrenoreceptor agonists (mirabegron)
relaxes detrusor mm and increases bladder capacity
do not use if uncontrolled severe HTN, renal, liver disease
Botox more likely to have complete relief of UUI
SE UTI and retention
behavioral for UUI and/or SUI
pelvic floor exercises PT
weight loss
dietary/fluid modification/bladder training
devices
surgical for UUI and/or SUI
SUI: urethral bulking agents or mid urethral sling
lack of urethral mobility associated with increase in failure of sling–do bulking agents instead
UUI: sacral neuromodulation ofr refractory UUI
simple fistulectomy procedure
close in 3 separate layers
rectal submucosa, muscularis, vaginal mucosa
anterior rectal wall edges inverted with interrupted submucosal 3-4.0 vicryl
2.0 vicryl in muscularis of anterior rectal wall to remove tension from first suture line
puborectalis muscle reapproximated to remove tension off underlying layers
vaginal mucosa re-approximated
treatment of ectopic pregnancy
expectant management: stable patient hCG <200; 88% will experience spontaneous resolution
methotrexate: folate antagonist (inhibits dihydrofolate reductase which converts dihydrofolate to tetrahydrofolate)
SE: stomatitis and conjuctivitis; rare–gastritis, enteritis, dermatitis, pneumoniitis, alopecia, LEFTs, bone marrow suppresion
avoid folate, NSAIDs, sunlight
surgery: ruptured, unstable, stable intact patient with counseling
contraindications to MTX for ectopic
absolute: IUP, immunosuppresion, blood dyscrasia (anemia/leukopenia/thrombocytopenia), sensitivity to mtx, active pulmonary disease (not asthma), active PUD, clinically important hepatic or renal dysfunction, breastfeeing, ruptured ectopic, hemodynamically unstable, not reliable for follow up
relative: FHR, size >4cm, hCG>5,000, declines blood transfusions
Dosage MTX for ectopic
single dose: 50mg/m2 IM day 1; check hcg D4 and D7–should drop >15% , follow weekly thereafter
Can give another dose if inappropriate drop
two dose regimen: 50mg/m2 on D1 and D4; consider for hCG>3000 or adnexal mass >2cm;
multidose: 1mg/Kg of D1, 3, 5, 7/leucovorin .1mg/kg on D2, 4, 6, 8–used for cornual or cervical ectopics
heterophile hcg
usually from animals (think lab techs, vets, farmers)
urine pregnancy test will be negative
serum levels usually <1000
CREST tubal ligation failure reates
(type; 5 yr failure per 1000; 10 year failure per 1000; ectopic risk per 1000)
Non PP BTL; 13/-;-
PP BTL; 6; 7.5; 1.5
Copper IUD; 14;-;-
Progesterone IUD; 5; -;-
bipolar cautery; 16.5; 25; 1.7-17
bands; 10; 20; 7.3
clips; 30; 40; 8.5
most common complication after GYN surgery
SSI
superficial incisional, deep incision abscess, pelvic or vaginal cuff cellulitis or abscess
RF: BMI >=30, periop hyperglycemia, coexistent infection, smoking, vaginal colonization, depth of subQ >=3cm, MRSA, immunosupression, poor nutrition
pre op measures: treat all infections remote from surgical site; no shaving–clipping of hair if needed; control blood sugar <200; shower/bath with soap/antiseptic night before surgery; vaginal prep with 4% CHG or iodine, skin prep, abx
surgical procedures requiring abx ppx
hysterectomy, AP repair, vaginal sling, laparotomy (no entry into bowel/vagina–may consider)
Ancef 2g (3g if >120kg)
hsg chromotubation if hx of PID or abnml tubes found–doxy 100mg BID x5 days
induced Ab or pregnancy d&C; doxy 200mg pre procedure x1
redose ancef if ebl >1500 or surgery >4hrs
PCN allergic: clinda 900mg x1 + gent 5mg/kg x1–redose clinda at 6hrs
can use aztreonam 2g instead of gent redose at 4hrs
MRSA–give vancomycin ppx 15mg/kg x1
can use flagyl 500mg)
urovaginal fistula work up
dual tampon test: saline and dye in bladder; pyridium and tampon in vagina–blue is from bladder; orange is from ureter
retrograde pyelography: ureteral integrity
IVP: less useful fro identifying and disruption fo urethral integrity
CT urogram: identify fistula site (cysto to rule out bladder injury)
medical management of fibroids
address bleeding symptoms
GnRH ANTAGONIST (elagolix 300mg) with hormonal add back (1mg estradiol/0.5mg norethindrone); spproved x2yrs
SE: hot flushes and headache
90% with <80cc monthly blood loss at 1 year
Mrena IUD: expulsion higher if myomas distort uterine cavity
40% amenorrhea by 1 year
OCPs
TXA: antifibrinolytic–presents fibrin degradation 1300mg x5 days
bleeding AND bulk
GnRH agonist (Lupron): limited to 6 months iwthout add therapy and 12mo with –use as a bridge to other therapies
complications of UAE
major 12%
unplanned hysterectomy (uterine perforation/intraperitoneal injury); UA perforation/hemorrhage
rehospitalization; bacteremia from arteriotomuy; myometritis
ovarian failure, PE
minor 21-64% symptommatic degeneration, postembolization syndrome pain fever nausea, myometrial infarction/necrosis, pelvic infection, discharge
non ovarian cancer causes of elevated CA-125
endometriomas
pregnancy
PID
non-gyn malignancy
inflammatory conditions SLE/IBD
gonorrhea treatment
dual therapy no longer recommended
ceftriaxone 1g IM x1
expedited partner treatment; 800mg cefixime PO x1 (plus 100mg doxycycline PO BID if chlamydia unknown)
expedited partner treatment
abstain x7 dys
AUB
PALM-COEIN
Polyps
Adenomyosis
Leiomyoma
Malignancy
Coagulopathy
Ovulatory dysfunction
Iatrogenic
Not otherwise specified
EMB >45; younger if RF
benign breast lesions
non-proliferative cysts
proliferative without atypia: fibroadneoma/intraductal papilloma
atypical hyperplasia–atypical ductal hyperplasia/atypical locular hyperplasia
dense breast confer moderate increased risk of malignancy
atypical ductal and lobular hyperplasia have 4 fold risk of of invasive malignancy; lobular carcinoma in situ is a risk marker for future malignancy
work up of a breast mass
imaging based on age:
diagnostic mammogram if >30; US usually required for further evaluation
US <30; determines if solid or cystic
aspiration: indicated for complex cyst or simple cyst that is symptommatic or patient anxiety
excision/biopsy: suspicious solid palpable mass, non-palpable suspicious mammo finding; aspiration with BI-RADS 3 (bloody fluid if positive cytolgoy, mass fails to resolve), associated with bloody nipple discharge or ulceration
atypical hperplasia or LCIS
annual mammogram >30
clinical breast exam q6-12mo
RR recommended (Tamoxifen)
annual MRI if lifetime risk >20-25%
most common cuase of bloody nipple discharge
benign intraductal papilloma
most common cause for a solid breast mass
fibroadenoma
Breast MRI indicated
BRCA1/2
1st degree relaitve is BRCA1/2 and patient not yet tested
lifetime risk of breast cancer >20%
chest radiation between 10-30yrs
cowden and other genetic syndromes
complete v partial mole
partial: 69xxx or xxy; fetus can be present; uterine size is small; theca lutein cysts are rare; GTN risk <5%
complete: 46xx or xy (paternal only); fetus absent; large uterus, theca lutein cysts are common; GTN risk 15-20%
theca lutein cysts are from high hcg levels
treatment of choice for molar: suction curettage followed by sharp curretage; hysterectomy if child bearing complete
post op followup: contraception
hcg weekly until negative
for partial can stop after first negative hcg
for complete do monthly x3
concern for post molar GTN
increasing hCG>10% accross 3 values over a 2 week period
plateauing hCG: 4 measurements that remain within 10% over at least 3 weeks
GTN
invasive mole
choriocarcinoma
PSTT
epithelioid trohpoblastic tumor
FIGO and GTN
age
duration from antecedent pregnancy
type of pregnancy
pre treatment hcg
largest tumor size
site of mets
number of mets
history of failed chemo
most common causes of cancer death in women
lung
breast
colon
pancreas
ovary
histopathology of lichen sclerosis
loss of rete pegs, thinned epidermins, hyperkeratosis
histopathology of papillary hidradenoma
appears malignant under low poer but benign on high power
histopathology of condyloma
koilocytosis: small shriveled nuclei in upper layer of epidermis
papillomatosis: exaggerated rete pegs
acanthosis: increased melanin layer
hyperkeratosis: thickened keratin layer
parakeratosis: nuclei in superficial layer of epidermis
histopathology of dysgerminoma
lymphocyte infiltrated stroma (large vesicular cells with clear cytoplasm that resember fried eggs)
histopathology of krukenburg tumor
signet ring cells
coffee bean nublei
brenner tumor and granulosa cell tumor
langhans giant cell
multinucleated gian cell with nuclei arranged along periphery of cell with opening at one end (horse appearance)
pathognomonic for TB